DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/c8e1aa/global_drug_elutin) has announced the addition of the "Global Drug Eluting Stent Market 2008-2012" report to their offering.
Drug Eluting Stents are used for the treatment of heart patients to prevent the need for more-invasive procedures, such as coronary artery bypass surgery. This reduces the need for repeated hospitalization and angioplasty procedures, thus reducing risks due to complications such as heart attack and stroke.
The Global Drug Eluting Stent market has been registering a significant growth in the recent past. This market is witnessing a consolidation of major players through strategic alliances. Moreover, the Drug Eluting Stent providers are looking forward to expand their product portfolio to provide a full range of interventional therapies to the physicians and patients.
The growth in the demand for the Drug Eluting Stent is due to its increasing acceptance as a viable treatment. Moreover, the growth is fueled by the robust economic growth and a greater adoption of social security schemes in the Asian regions. There are a large number of patients opting for these treatments so as to enhance their quality of life. Further, developed countries provide easy reimbursement options for higher-priced Drug Eluting Stent, which makes them affordable for patients. Moreover reimbursements by national medical savings schemes play a crucial role in the demand for the Drug Eluting Stents.
Key Topics Covered:
1. Introduction
2. Global Drug Eluting Stent Market Size & Forecast
3. Geographic Segmentation
4. Market Trends of Global Drug Eluting Stent
5. Sales Drivers of Global Drug Eluting Stent
6. Market Challenges for Global Drug Eluting Stent
7. Market Vendors of Drug Eluting Stent
Companies Mentioned:
- Abbott Laboratories
- Biosensors International Group Limited
- Boston Scientific
- Johnson & Johnson
- Medtronic, Inc
For more information visit http://www.researchandmarkets.com/research/c8e1aa/global_drug_elutin
